Skip to main content
SpringerLink
Log in

Peptic Ulcer Disease

Overview and Management

  • Chapter
Diseases of the Gastroesophageal Mucosa

Part of the book series: Clinical Gastroenterology ((CG))

  • 102 Accesses

Abstract

In the past decade, the causes of peptic ulcer disease (PUD) have been clarified. Infection with Helicobacter pylori has emerged as the most frequent cause, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) has become an increasingly important cause. PUD, a term encompassing both gastric and duodenal ulcers continues to be a serious medical problem, primarily because of its ubiquity: approximately 500,000 new cases develop each year in the United States and 4 million recur. The high prevalence of PUD results in significant morbidity, mortality, and economic costs. Over 80% of patients experience pain or gastrointestinal bleeding; more than 5000 patients die each year of ulcer complications, and the economic costs of this are staggering. The estimated annual direct costs, such as physician visits, diagnostic investigations, and medications for treatment of patients with PUD is approx $ 8–10 million. The indirect costs, such as lost time from work, are similar. The total cost of antiulcer medications is estimated to be at least $3 billion/yr in the United States. This chapter reviews the changing epidemiology of PUD, its causes, and its management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kurata JH, Corboy ED. (1988) Current peptic ulcer trends: an epidemiological profile. J Clin Gastroenterol 10: 259–268.

    Article  PubMed  CAS  Google Scholar 

  2. Gustaysson S, Kelly KA, Melton LJ III, Zinmeister AR. (1988) Trends in peptic ulcer surgery: a population-based study in Rochester, Minnesota, 1956–1985. Gastroenterology 94: 689–694.

    Google Scholar 

  3. Walker LJ Jr. (1988) Trends in the surgical management of duodenal ulcer: a fifteen year study. Am J Surg 155: 436–438.

    Article  PubMed  Google Scholar 

  4. Bloom BS, Kroch E. (1993) Time trends in peptic ulcer disease and in gastritis and duodenitis:mortality, utilization, and disability in the United States. J Clin Gastroenterol 17: 333–342.

    Article  PubMed  CAS  Google Scholar 

  5. Primatesta, Goldacre MJ, Seagrott V. (1994) Changing patterns in the epidemiology and hospital care of peptic ulcer. Int J Epidemiol 23: 1206–1217.

    Article  PubMed  CAS  Google Scholar 

  6. Munnangi S, Sonnenberg A. (1997) Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Int Med 157: 1489–1494.

    Article  CAS  Google Scholar 

  7. Sonnenberg A. (1987) Changes in physician visits for gastritis and duodenal ulcer in the United States during 1958–1984 as shown by National Disease and Therapeutic Index. Dig Dis Sci 32: 1–7.

    Article  PubMed  CAS  Google Scholar 

  8. Asaka M, Kimura T, Kudo M, et al. (1992) Relationship of Helicobacter pylori to serum pepsinogen in an asymptomatic Japanese population. Gastroenterology 102: 760.

    PubMed  CAS  Google Scholar 

  9. Sprung DJ, Apter MN. (1998) What is the role of Helicobacter pylori in peptic ulcer and gastric cancer outside the big cities? J Clin Gastroenterol 26 (1): 60–63.

    Article  PubMed  CAS  Google Scholar 

  10. Pounder RE, Ng D. (1995) The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 9 (Suppl 2): 33.

    PubMed  Google Scholar 

  11. Torres J, Leal-Herrera Y, Perez-Perez G, et al. (1998) A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 178: 1089.

    Article  PubMed  CAS  Google Scholar 

  12. Armstrong CP, Blower AL. (1987) Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28: 527–532.

    Article  PubMed  CAS  Google Scholar 

  13. Larkei EN, Smith JL, Lidsky MD, Graham DY. (1987) Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic steroidal anti-inflammatory drug use. Am J Gastroenterol 82: 1153–1158.

    Google Scholar 

  14. Graham DY, Agrawal NM, Roth SH. (1988) Prevention of NSAID-induced gastric ulcer with misoprostol: multicentric, double-blind, placebo-controlled trial. Lancet 2: 1277–1280.

    Article  PubMed  CAS  Google Scholar 

  15. McGuigan JE. (1988) Zolliger-Ellison syndrome and other hypersecretory states. In: Gastrointestinal disease, 6th ed., Sleisenger, M, Fordtran, J (eds.), Philadelphia: WB Saunders 677–695.

    Google Scholar 

  16. Jyotheeswaran S, Shah AN, Jin HO, et al. (1998) Prevalence of Helicobacter pylori in peptic ulcer recurrence in greater Rochester, NY. Is empirical triple therapy justified? Am J Gastroenterol 93: 574–578.

    Article  PubMed  CAS  Google Scholar 

  17. Jensen DM, King J, Gornbein J, Cheng S. (1997) Prevalence of H. pylori and aspirin or NS AID utilization in patients with ulcer hemorrhage: results of screening for a large multicenter U.S. trial. Gastroenterology 114: A161.

    Article  Google Scholar 

  18. Sprung DJ, Gano B. (1997) Natural history of duodenal ulcer disease and how it relates to H.pylori: a community study. Am J Gastroenterol 92: A286.

    Google Scholar 

  19. Peterson WL, Ciociola AA, Sykes DL, et al. (1996) RBC H. pylori Study Group. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment Pharmacol Ther 10: 251–262.

    Article  PubMed  CAS  Google Scholar 

  20. Lee J, Melamed M, Vaughn C, Kaloo A. (1999) The vanishing role of Helicobacter pylori as thecausative agent in duodenal ulcers. A prospective study in a tertiary care center. Am J Gastroenterol 94: 2611.

    Google Scholar 

  21. Di Ballista R, Bierti L, Benassi R, et al. (1997) Prevalence and risk factors in (Helicobacterpylori)-negative peptic ulcer in an area of Northern Italy. Gastroenterology 112: A1020.

    Google Scholar 

  22. McColl KEL, El-Nujumi AM, Chittajallu RS, et al. (1993) A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 34: 762–768.

    Article  PubMed  CAS  Google Scholar 

  23. Gisbert JP, Blanco M, Mateos JM, et al. (1999) H. pylori-negative duodenal ulcer prevalence and causes in 774 patients. Dig Dis Sci 44 (11): 2295–2302.

    CAS  Google Scholar 

  24. Bolton RP, Clarke K, Bryant S, Radford J. (1997) Helicobacter pylori and peptic ulcer disease in primary care: is a systematic `identify and treatment’ strategy worthwhile? Gut 41: A89.

    Google Scholar 

  25. Laine L, Hopkins RJ, Giraldi LS. (1998) Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated? A meta-analysis of rigorously designed trials. Am J Gastroenterol 93: 1409–1415.

    PubMed  CAS  Google Scholar 

  26. Nensey YW, Schubert TT, Bologna SD, Ma CK. (1991) Helicobacter pylori-negative duodenal ulcer. Am J Gastroenterol 91: 15–18.

    CAS  Google Scholar 

  27. Prach AT, Senior BW, Hopwood D, et al. (1997) H. pylori infection status in relation to antibiotic and non-steroidal prescribing in patients on maintenance treatment for chronic duodenal ulcer. Eur J Gastroenterol Hepatol 9: 251–256.

    CAS  Google Scholar 

  28. Hyvarinen H, Salmenkyla S, Sipponen P. (1996) Helicobacter pylori-negative duodenal and pyloric ulcer: role of NSAIDs. Digestion 57: 305–309.

    CAS  Google Scholar 

  29. Cutler AF, Haystad S, Ma CK, et al. (1995) Accuracy of invasive and noninvasive tests to diagnose Helicobacterpylori infection. Gastroenterology 109: 136–141.

    Article  PubMed  CAS  Google Scholar 

  30. Luthra GK, DiNuzzo WK, Growe SE. (1998) Comparison of biopsy and serological methods of diagnosis of Helicobacter pylori infection and the potential role of antibiotics. Am J Gastroenterol 93: 1291–1296.

    Article  PubMed  CAS  Google Scholar 

  31. Weil J, Bell GD, Powell K. (1991) Omeprazole and H. pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther 5: 303–313.

    Google Scholar 

  32. Chey WD, Spybrook M, Carpenter S, et al. (1996) Prolonged effect of omeprazole on the 14C-urea breath test. Am J Gastroenterol 91: 89–92.

    PubMed  CAS  Google Scholar 

  33. Goddard AF, Logan RP, Atherton JC, et al. (1997) Healing of duodenal ulcer after eradication of Helicobacter heilamanni. Lancet 349: 1815–1816.

    CAS  Google Scholar 

  34. Yeomans ND, Kolt SD. (1996) Helicobacterheilamanni (formerly Gastrospirillum). Association with pig and human gastric pathology. Gastroenterology 111: 244–247.

    Google Scholar 

  35. Debongnie JC, Donay M. Mairesse J, et al. (1998) Gastric ulcers and Helicobacter heilamanni. Eur J Gastroenterol Hepatol 10: 251–254.

    Article  PubMed  CAS  Google Scholar 

  36. Dietrich C, Wiesel P, Neiger R, et al. (1998) Presence of multiple “Helicobacter heilamanni” strains in an individual suffering from ulcers and in his two cats. J Clin Microbiol 36: 1366–1370.

    Google Scholar 

  37. Sonnenberg A, Muller-Lissner SA, Vogel E, et al. (1981) Predictors of duodenal ulcer healing and relapse. Gastroenterology 81: 1061–1067.

    PubMed  CAS  Google Scholar 

  38. Sonnenberg A, Townsend WF. (1991) Testing for H. pylori in the diagnosis of Zollinger-Ellison syndrome. Am J Gastroenterol 86: 606–608.

    PubMed  CAS  Google Scholar 

  39. Ippoli AF, Sturdevant RAL, Isenberg JI, et al. (1978) Cimetidine versus intensive antacid therapy for duodenal ulcer. Gastroenterology 74: 393.

    Google Scholar 

  40. Jorde R, Bostad L, Burhol PG. (1986) Asymptomatic gastric ulcer. A follow-up study in patients with previous gastric ulcer disease. Lancet 1: 119.

    Article  PubMed  CAS  Google Scholar 

  41. Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in peptic ulcer disease. Aliment Pharmacol Ther 59(Suppl 2):.

    Google Scholar 

  42. Levine MS. (1993) Role of the double-contrast upper gastrointestinal series in the 1990s. Gastroenterology 105: 1583.

    Google Scholar 

  43. Glick SW. (1994) Duodenal ulcer. Radiol Clin North Am 34: 1259.

    Google Scholar 

  44. Dooley CP, Larson AW, Stace NH et al. (1984) Double-contrast barium meal and upper gastrointestinal radiography. Ann Intern Med 101: 538.

    PubMed  CAS  Google Scholar 

  45. Soll AH. (1998) Peptic ulcer and its complications. In: Gastrointestinal disease, 6th ed., Sleisenger M and Fordtran J, eds., Philadelphia: WB Saunders, pp. 620–678.

    Google Scholar 

  46. Gelfand DW, Ott DJ, Mnitz HA, Chey YM. (1984) Radiology and endoscopy: a radiologic view point. Ann Intern Med 101: 550–552.

    PubMed  CAS  Google Scholar 

  47. Herlinger H, Glanville JL, Kreel L. (1977) An evaluation of the double contrast barium meal (DCBM) against endoscopy. Clin Radiol 28: 307–314.

    Article  PubMed  CAS  Google Scholar 

  48. Brown P, Salmon PR, Burwood RI, et al. (1978) The endoscopic, radiological, and surgical findings in chronic duodenal ulceration. Scand J Gastroenterol 13: 557–560.

    Article  PubMed  CAS  Google Scholar 

  49. Cotton PB, Shorvon PJ. (1984) Analysis of endoscopy and radiography in the diagnosis, follow-up and treatment of peptic ulcer disease. J Clin Gastroenterol 13: 383–403.

    CAS  Google Scholar 

  50. Longstreth, GF. (1992) Long-term costs after gastroenterology consultation with endoscopy versus radiography in dyspepsia. Gastrointest Endosc 38: 23.

    Article  PubMed  CAS  Google Scholar 

  51. Ganz I, Schaeffer M, Del Valle J, et al. (1991) Molecular cloning of a gene encoding the histamine H2-receptor. Proc Natl Acad Sci USA 488: 429–433.

    Article  Google Scholar 

  52. Ash A, Schild H. (1996) Receptors mediating some of the actions of histamine. Br J Pharmacol 27: 427–439.

    Google Scholar 

  53. Black JW, Duncan WAM, Durant CJ, et al. (1992) Definition and antagonism of histamine H2-receptors. Nature 236: 385–390.

    Article  Google Scholar 

  54. Feldman M, Burton ME. (1990) Histamine-2-receptor antagonists. Standard therapy for acid-peptic disease. N Engl J Med 323: 1672.

    Article  PubMed  CAS  Google Scholar 

  55. Lichtenstein DR, Wolfe MM. (1993) Histamine H2-receptor antagonists. In: Gastrointestinal Pharmacotherapy, Wolfe MM, ed., Philadelphia: WB Saunders, pp. 47–84.

    Google Scholar 

  56. Cantu TG, Korek JS. (1991) Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 114: 1027.

    PubMed  CAS  Google Scholar 

  57. Gladzuiva U, Koltz U. (1994) Pharmacokinetic optimization of the treatment of peptic ulcer in patients with renal failure. Clinical Pharmacokinet 27: 393.

    Article  Google Scholar 

  58. Reynolds JC. (1990) The clinical importance of drug interactions with antiulcer therapy. J Clin Gastroenterol 12: S54.

    Article  PubMed  Google Scholar 

  59. McCarthy DM. (1983) Ranitidineor cimetidine (editorial). Ann Intern Med 99: 551.

    PubMed  CAS  Google Scholar 

  60. Jensen RT, Collen MJ, Pandol SJ, et al. (1983) Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 308: 883.

    Article  PubMed  CAS  Google Scholar 

  61. Peterson WL, Sturdevant RA, Franks HD, et al. (1977) Healing of duodenal ulcer with an antacid regimen. N Engl J Med 297: 341.

    Article  PubMed  CAS  Google Scholar 

  62. Aymard JP, Aymard B, Netter P, et al. (1988) Hematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp 3: 430.

    PubMed  CAS  Google Scholar 

  63. Smallwood RA, Berlin RG, Castagnoli N, et al. (1995) Safety of acid-suppressing drugs. Dig Dis Sci 40: 63S.

    Google Scholar 

  64. Kumar A. (1990) Cimetidine: an immunomodulator. Ann Pharmaco Ther 24: 289.

    CAS  Google Scholar 

  65. Lewis H. (1987) Hepatic effects of drugs used in the treatment of peptic ulcer disease. Am J Gastroenterol 82: 987.

    PubMed  CAS  Google Scholar 

  66. Black M. (1987) Hepatotoxic and hepatoprotective potential of histamine receptor antagonists. Am J Med 83 (Suppl 6A): 68.

    Article  PubMed  CAS  Google Scholar 

  67. Hinrichsen H, Halabi A, Kirch W. (1995) Clinical aspects of cardiovascular effects of H2 -receptor antagonists. Eur J Clin Invest 25 (Suppl 1): 47.

    PubMed  Google Scholar 

  68. Burget DW, Cliverton SG, Hunt RH. (1990) Is there an optimal decree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 435.

    Google Scholar 

  69. Gitlin N, McCullough AJ, Smith JL, et al. (1987) A multicenter, double-blind, randomized placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease. Gastroenterology 92: 48–53.

    PubMed  CAS  Google Scholar 

  70. Wilder-Smith CH, Ernst T, Gennoni M, et al. (1990) Tolerance to oral H2-receptor antagonists. Dig Dis Sci 35: 976–983.

    Article  PubMed  CAS  Google Scholar 

  71. Smith JTL, Garey C, Nwokolo CU, Pounder RE. (1990) Tolerance during 8 days of high-dose H2 -blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 4 (Suppl): 47–63.

    PubMed  CAS  Google Scholar 

  72. Lachman L, Howden CW. (2000) Twenty-four hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. Am J Gastroenterol 95: 57–62.

    Article  PubMed  CAS  Google Scholar 

  73. Sandvik AK, Brenna E, Waldum HL. (1997) The pharmacological inhibition of gastric acid secretion: tolerance and rebound. Aliment Pharmacol Ther 11: 1013–1018.

    Article  PubMed  CAS  Google Scholar 

  74. Nwokolo CU, Smith JTL, Sawyerr AM, et al. (1991) Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2-receptor blockade. Gut 32: 1455–1460.

    Article  PubMed  CAS  Google Scholar 

  75. Besancon M, Simon A, Sachs G, et al. (1997) Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272: 2438–2446.

    Article  Google Scholar 

  76. Cederberg C, Anderson T, Skaanberg I. (1989) Omeprazole: Pharmacokinetics and metabolism in man. Scand J Gastroenterol 24 (Suppl 166): 33.

    Article  Google Scholar 

  77. Bertilsson L. (1995) Geographical/interracial differences in polymorphic drug oxidation. Currentstate of knowledge of cytochrome P450 (CYP) 2D and 2 C19. Clin Pharmacokinet 29: 192.

    Article  PubMed  CAS  Google Scholar 

  78. Huber R, Kohl B, Sachs G, et al. (1995) The continuing development of proton pump inhibitors with reference to pantoprazole. Aliment Pharmacol Ther 9: 363.

    Article  PubMed  CAS  Google Scholar 

  79. Dellrolat Landes BD, Petite JP, Flouvat B. (1995) Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 28: 458.

    Article  Google Scholar 

  80. Yeomans ND. (1994) Omeprazole: short-and long-term safety. Adverse Drug React Toxicol Rev 13: 145.

    PubMed  CAS  Google Scholar 

  81. Freston JW. (1994) Omeprazole, hypergastrinemia, and gastric carcinoid tumor. Ann Intern Med 121: 232.

    PubMed  CAS  Google Scholar 

  82. Klinkenberg-Knol EC, Nelis F, Dent J, et al. (2000) Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118: 661–669.

    Article  PubMed  CAS  Google Scholar 

  83. Lalkin A, Loebstein R, Addis A, et al. (1998) The safety of Omeprazole during pregnancy. A multicenter prospective controlled study. Am J Obstet Gynecol 179: 727–730.

    Article  PubMed  CAS  Google Scholar 

  84. Freston JW. (1997) Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am J Gastroenterol 92: 515–57S.

    Google Scholar 

  85. Poynard T, Lemaire M, Agostinii H. (1995) Meta-analysis of randomized clinical trials comparing Lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer. Eur J Gastroenterol Hepatol 7: 661–665.

    PubMed  CAS  Google Scholar 

  86. Bader JP, Delchier JC. (1994) Clinical efficacy of pantoprazole compared with ranitidine. Aliment Pharmacol Ther 8 (Suppl 1): 47–52.

    PubMed  Google Scholar 

  87. Tarnawski A, Stachura J, Sareh IJ, et al. (1991) Prostacyclin, endothelial cell growth factor and antacid stimulate angiogenesis in injured gastric mucosa. Gastroenterology 100: 174.

    Google Scholar 

  88. Weberg R, Berstad K, Berstad A. (1990) Acute effects of antacids on gastric juice components in duodenal ulcer patients. Eur J Clin Invest 20: 511.

    Article  PubMed  CAS  Google Scholar 

  89. Weberg R, Berstad A, Lange O. (1985) Duodenal ulcer healing with four antacid tablets daily. Scand J Gastroenterol 29: 1041–1050.

    Article  Google Scholar 

  90. Rydning A, Weberg R, Lange 0, Berstad A. (1986) Healing of benign gastric ulcer with low dose antacids and fiber diet. Gastroenterology 91: 56–61.

    PubMed  CAS  Google Scholar 

  91. Weberg R, Auburt E, Dahlberg O, et al. (1988) Low dose antacids or cimetidine for duodenal ulcer? Gastroenterology 95: 465–1469.

    Google Scholar 

  92. Kanturek SJ, Brzozowski T, Bielanski W, et al. (1988) Epidermal growth factor in the gastroprotective effect and ulcer-healing actions of sucralfate in rats. Gut 29: 894–902.

    Article  Google Scholar 

  93. Szabo S, Hollander D. (1989) Pathways of gastrointestinal protection and repair: mechanisms of action of sucralfate. Am J Med 86: 23–31.

    Article  PubMed  CAS  Google Scholar 

  94. Shorrock C, Rees W. (1990) Effect of sucralfate on human gastric bicarbonate secretion and local concentrations in serum. Antimicrob Agents Chemo Ther 34: 931–933.

    Article  Google Scholar 

  95. Brandstaetter G, Kratochvil P. (1985) Comparison of two sucralfate dosages (2gm twice daily versus lgm four times a day) in duodenal ulcer healing. Am J Med 79 (Suppl 2C): 36–38.

    Article  PubMed  CAS  Google Scholar 

  96. Marks IN, Wright JP, Gilinsky NH, et al. (1986) A comparison of sucralfate dosage schedule in duodenal ulcer healing. Two gram twice a day versus one gram four times a day. J Clin Gastroenterol 8: 419–423.

    Article  PubMed  CAS  Google Scholar 

  97. Garrets JC, Godley PJ, Peterie JD, et al. (1990) Sucralfate significantly reduces ciprofloxacin concentration in serum. Antimicrob Agents Chemo Ther 34: 931–933.

    Article  Google Scholar 

  98. Glise H, Carling L, Hallerback B, et al. (1986) Short-term treatment of duodenal ulcer. A comparison of sucralfate and cimetidine. Scand J Gastroenterol 21: 313–320.

    Article  PubMed  CAS  Google Scholar 

  99. Lam SK, Lau WY, Lai CL, et al. (1985) Efficacy of sucralfate in corpus, prepyboric, and duodenal ulcer-associated gastric ulcers. A double-blind, placebo-controlled study. Am J Med 7 (Suppl 2C): 24–31.

    Article  Google Scholar 

  100. Graham DY, Yamaoka Y. (1998) H. pylori and Cag A: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 3: 141–152.

    Google Scholar 

  101. Labenz J, Tillenburg B, Peitz U, et al. (1997) Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 92: 576–578.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Shyam Varadarajulu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James W. Freston MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, University of Connecticut Health Center, Farmington, CT, USA

    James W. Freston MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Varadarajulu, S., Freston, J.W. (2001). Peptic Ulcer Disease. In: Freston, J.W. (eds) Diseases of the Gastroesophageal Mucosa. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-103-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-103-9_1

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9642-0

  • Online ISBN: 978-1-59259-103-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation